Pay in 4 interest-free payments of $6.70 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Immunogenicity: The FDA classified BPC-157 in Category 2 for bulk drug substances, citing possible safety issues in compounding (immunogenicity, impurities, and insufficient safety evidence for suggested administration routes)
Thus, to illustrate these combining points (i.e., [13, 44, 63]), considering that white matter injury is the major cause of functional loss after SCI [45, 52], it is important to note that cysts and the loss of axons instead of hemorrhagic areas were observed in the white matter in all of the controls beginning on day 7 and that the rats exhibited a tail motor score that persisted with only small improvements, sustained debilitation, sustained tail spasticity until the end of the experiment (day 360), a decrease in the number of large myelinated axons in the caudal nerve, a higher MUP (giant potential) in the tail muscle, and a group of atrophic fibers that likely represented a large unit that acquired many fibers through collateral reinnervation and then degenerated
Room Temperature: Keep this product at a controlled room temperature between 15C - 30C to preserve its quality
Key Takeaways Typical daily dose: 250500 mcg Inject near injury for localized recovery Oral form is best for gut healing Cycle length: 26 weeks depending on severity Stack with TB-500 or CJC-1295 for optimal results Always use sterile technique and medical guidance Who Should Get Medical Guidance Before BPC-157
Safety profiles appear generally acceptable, though rare adverse events and uncertain long-term risks necessitate ongoing vigilance
For sensitive applications such as gene-expression profiling or receptor-binding work, the difference between 95% and 99% purity is operationally significant
